Many antiseizure medications (ASMs) affect ion channel function. We investigated whether ASMs alter the risk of cardiac events in patients with corrected QT (QTc) prolongation. The study included people from the Rochester-based Long QT syndrome (LQTS) Registry with baseline QTc prolongation and history of ASM therapy (n = 296). Using multivariate Anderson-Gill models, we assessed the risk of recurrent cardiac events associated with ASM therapy. We stratified by LQTS genotype and predominant mechanism of ASM action (Na + channel blocker and gamma-aminobutyric acid modifier.) There was an increased risk of cardiac events when participants with QTc prolongation were taking vs off ASMs (HR 1.65, 95% confidence interval [CI] 1.36-2.00, P < 0.001). There was an increased risk of cardiac events when LQTS2 (HR 1.49, 95% CI 1.03-2.15, P = 0.036) but not LQTS1 participants were taking ASMs (interaction, P = 0.016). Na + channel blocker ASMs were associated with an increased risk of cardiac events in participants with QTc prolongation, specifically LQTS2, but decreased risk in LQTS1. The increased risk when taking all ASMs and Na + channel blocker ASMs was attenuated by concurrent beta-adrenergic blocker therapy (interaction, P < 0.001). Gamma-aminobutyric acid modifier ASMs were associated with an increased risk of events in patients not concurrently treated with beta-adrenergic blockers. Female participants were at an increased risk of cardiac events while taking all ASMs and each class of ASMs. Despite no change in overall QTc duration, pharmacogenomic analyses set the stage for future prospective clinical and mechanistic studies to validate that ASMs with predominantly Na + channel blocking actions are deleterious in LQTS2, but protective in LQTS1. (Translational Research 2018;191:81-92) Research in April 2017. 
INTRODUCTION
ASMs are associated with an increased risk of sudden cardiac death (SCD) and sudden unexpected death in epilepsy (SUDEP.) [1] [2] [3] Many antiseizure medications (ASMs) alter ion channel activity. 3 For example, phenytoin, carbamazepine, and lamotrigine are Na + channel blockers, while phenobarbital is a gamma-aminobutyric acid (GABA) enhancing drug. [4] [5] [6] Many ASMs have multiple effects, some of which are incompletely understood. Since there is overlap in subtypes of ion channels expressed in the heart and brain, 7 it is important to assess the cardiac safety of ASMs.
There is not a clear consensus whether ASMs are associated with changes in electrocardiogram (ECG) measures and risk of arrhythmias. [8] [9] [10] [11] [12] Cellular expression studies indicate that several ASMs block the rapid delayed rectifier K + current (IKr), which contributes to action potential repolarization in the heart. 13, 14 Yet, in both healthy and epilepsy patient populations, these ASMs that block IKr are not associated with corrected QT (QTc) prolongation on the cardiac ECG or increased risk of arrhythmias. 10, [15] [16] [17] Although none of the ASMs examined in this study are on the Credible Meds list of drugs that increase the risk of torsades-de-pointes, 18 it remains unknown whether ASMs are safe in patients with underlying inherited or acquired alterations in cardiac electrical function.
Long QT syndrome (LQTS) mutations disturb the balance between depolarizing and repolarizing currents throughout the cardiac activation-recovery process, leading to QT c prolongation and an increased risk of arrhythmias and SCD. 19 There is also a strong association between LQTS and seizures. [20] [21] [22] We recently showed that LQTS patients with seizures exhibit an increased risk for ventricular tachyarrhythmias. 20 As many LQTS patients take ASMs for seizures, and ASMs are used for pain control and as mood stabilizers, it is important to assess whether ASMs affect the risk of cardiac arrhythmias in these populations.
Using the Rochester-based LQTS Patient Registry, we compared the rate and risk of recurrent cardiac events when participants with QTc prolongation and a history of ASM therapy were taking (on) vs off ASMs. Since the registry includes a relatively large number of LQTS1 (n = 46) and LQTS2 (n = 76) participants on ASMs, we specifically assessed whether there were LQTS genotype differences in the risk of cardiac events when on ASMs. Owing to differing mechanisms of ASM action, we also assessed the risk of cardiac events when LQTS participants were on each or a combination of classes of ASMs (i.e., Na + channel blocker, GABA modifier, and concurrent Na + channel blocker and GABA modifier ASMs). We hypothesized ASMs are associated with an increased risk of cardiac events in patients with reduced repolarization reserve (i.e., those with QTc prolongation).
METHODS
Study cohort. The Rochester-based LQTS Registry provides a wealth of clinical, pharmacologic, and genetic information about LQTS probands and their affected and unaffected family members. 19 LQTS diagnosis was made by QTc prolongation and/or LQTS genetic testing. Information was collected from extensive baseline/ enrollment and yearly follow-up participant questionnaires, genetic reports, and physician reports. Information important to this study included results from genetic testing, the dates of ECG measurements and cardiac events, as well as the name and start (on) and end (off) date of taking each medication. Patient reported information was confirmed by reviewing the initial and yearly physician reports. The period on ASMs and beta-adrenergic blockers was defined as the dates the participant reported in AT A GLANCE COMMENTARY Auerbach DS, et al.
Background
Long QT syndrome (LQTS) is due to mutations in ion channel genes expressed in the brain and heart. LQTS patients are at a high risk of arrhythmias and sudden death. As there is a high prevalence of seizures in LQTS, and antiseizure medications act on ion channels expressed in the brain and heart, it is important to assess the cardiac safety of ASMs in patients with LQTS.
Translational significance
Pharmacogenomic analyses indicate there are LQTS genotype and antiseizure medication class specific risks of cardiac events. These results establish the basis for future prospective clinical studies, and mechanistic cellular and animal studies.
the enrollment and yearly follow-up questionnaires being prescribed the medication, plus the dates the medication was listed in the medical records.
The study included consented participants with QTc prolongation and a history of ASM therapy, and stratified by LQTS genotype (LQTS1 vs LQTS2). Importantly, in every participant, there was a period where the participant was taking (on) an ASM, as well as off all ASMs. Therefore, we performed detailed assessments of the risk of recurrent cardiac events when on ASMs. The QT duration was defined from the start of the Q wave to the end of the T wave when it reached the isoelectric baseline and corrected for heart rate using the Bazett formula (QTc). Baseline QTc duration was measured from the initial ECG at enrollment. The patient cohort included those with QTc prolongation (male QTc > 450 ms, female QTc > 470 ms, n = 296); participants with QTc prolongation were subdivided into (1) LQTS1 genotype positive (n = 46), and (2) LQTS2 genotype positive (n = 76). Thirteen patients with LQTS3-12 mutations were included in the QTc prolongation group, but due to low numbers were not stratified by LQTS genotype. In the remaining 158 participants with QTc prolongation, the LQTS mutation was unknown. All LQTS genotype positive participants had only 1 mutant LQTS gene. Follow-up was from birth to 40 years of age, loss of follow-up, death, or December 2016, with no race/ethnicity or sex restrictions. The number of participants and total time on all ASMs and each class/combination of ASMs were similar in LQTS1 vs LQTS2 (Supplementary Table I) .
Outcome measures. Similar to our recent study, 20 cardiac events were defined as aborted cardiac arrest, SCD, and ventricular tachyarrhythmias (sustained ventricular tachycardia, torsades-de-pointes, and ventricular fibrillation). This information was documented in medical records, implantable cardiac defibrillator (ICD) interrogation, and telemetric/Holter monitoring, as well as ambulatory and in-hospital ECG recordings. In all groups, each type of cardiac event was documented. Outcome measures included (1) the rate of recurrent cardiac events when participants were taking (on) ASMs and off all ASMs (normalized to 100 person years) and (2) multivariate adjusted time-dependent risk of recurrent cardiac events when taking ASMs. As the underlying cause for each syncopal event was not known, it was not classified as a cardiac event, especially since this is a cohort of participants with a history of seizures. In addition, since episodes of nonsustained ventricular tachycardia might be missed, they were not classified as cardiac events. Supplementary Table II lists the ASMs taken by patients in the LQTS Registry, their predominant mechanism(s) of action, [4] [5] [6] 23 and the number of participants in each group that took each ASM. ASMs were classified by their predominant mechanism of action: (1) Na + channel blocker, (2) GABA modifier, and/or (3) other (e.g., Ca
2+
, synaptic vesicle protein 2A, and glutamate blockers.) Although ASMs may have additional known/unknown mechanisms of action, we limited our classification to their major mechanism(s) of action. ASMs with more than 1 major mechanism of action were classified in multiple groups (e.g., divalproex and topiramate.) We assessed the risk of cardiac events on each or a combination of classes of ASMs (Fig 1) . We also confirmed our results assessing the risk of cardiac events on a commonly used Na + channel blocker ASM (phenytoin) or GABA modifier ASM (phenobarbital), as well as high sensitivity analyses in participants with a history of cardiac events.
Study approval. The LQTS Registry is approved by the University of Rochester Research Subject Review Board (RSRB00025305). All data were handled in accordance with applicable laws and the Code of Ethics of the World Medical Association. HIPAA requirements for accounting for disclosure, consent, and withdrawal of consent were followed. Written informed consent was obtained from all participants/guardians in the study.
Statistics. In a cohort of participants with QTc prolongation and a history of ASM therapy, the risk of recurrent cardiac events associated with ASM usage was tested ASM class-specific analyses. Flow chart of ASMs grouped by the predominant mechanism of action, and the number of participants with QTc prolongation on each class of ASMs. NA, Na + channel (Na + Ch) blocker ASMs; GA, GABA modifier ASMs; Other, ASMs with the predominant mechanism of action other than Na + channel blockade and GABA modification. Several participants had a history of taking more than 1 ASM during followup. ASM, antiseizure medication; QTc, corrected QT; GABA, gamma-aminobutyric acid. using multivariate Andersen-Gill model recurrent event analysis (hazard ratio [HR] , 95% confidence interval [CI], P value). 95% of all participants with QTc prolongation developed ≤10 arrhythmic events. Participants were censored at 10 events to prevent participants who developed frequent cardiac events from having an undue influence on the risk assessments.
All risk assessments were performed adjusting for LQTS comorbidities, concomitant medications, and sex. Specifically, we adjusted for baseline QTc duration, betaadrenergic blockers were modeled using a time-dependent covariate, and we applied a nonparametric stratification for sex. Recurrent risk assessments on each or a combination of classes of ASMs were performed in 1 model using a categorical variable with 5 levels (Fig 1) (1) on Na + channel blocker ASMs, (2) on GABA modifier ASMs, (3) on other ASMs, (4) concurrently on Na + channel blocker and GABA modifier ASMs, and (5) off all ASMs (reference). The risk of recurrent cardiac events on other ASMs is not displayed as it is a heterogenous group of ASM mechanisms of action, and the number of participants and events were too low to calculate the risk.
To further explore the ASM class-specific risk of cardiac events, we assessed the risk of cardiac events associated with time-dependent phenytoin (Na + channel blocker ASM) and phenobarbital (GABA modifier ASM) use. For risk analyses on phenytoin and phenobarbital, we stratified for sex, and adjusted for baseline QTc duration, time-dependent beta-adrenergic blocker usage, and nonphenytoin or nonphenobarbital ASM therapy, respectively.
We tested for differences in the risk of cardiac events associated with time-dependent ASM use in LQTS1 vs LQTS2 participants, in the absence vs copresence of betaadrenergic blockers, and male vs female participants. We estimated the effects using interaction terms in the models and the P-values were reported for each comparison. Paired t tests were applied to assess differences in ECG measures on vs off ASMs, in participants that had at least 1 ECG measurement each on and off ASMs. Significance was defined as P < 0.05. All analyses were conducted using SAS software, version 9.4 (SAS Institute, North Carolina).
RESULTS
ASMs are associated with LQTS genotype-specific differences in the risk of cardiac events. The baseline characteristics were similar in LQTS1 and LQTS2 participants (Table I and Supplementary Table I ). There were no differences in sex, total time of follow-up, percentage with a history of beta-adrenergic blocker therapy, percentage of participants and time on ASMs, age of baseline ECG (i.e., enrollment), baseline QTc duration, and percentage of participants with a history of cardiac events in the LQTS1 vs LQTS2 groups. None of the ASMs are classified on the Credible Meds list of medications associated with an increased risk of torsades-de-pointes, even under certain conditions, such as LQTS, drug overdose, or coadministration of potentially harmful interacting drugs. 18 Yet, there was a 1.8-fold higher rate and increased adjusted risk of cardiac events when participants with QTc prolongation were taking (on) ASMs vs off all ASMs (HR 1.65, 95% CI 1.36-2.00, P < 0.001, Fig 2) . Also, while there were not enough events to calculate the risk of cardiac events when on ASMs, LQTS genotype negative participants with normal QTc durations (i.e., unaffected family members of the proband, n = 64) did not exhibit an increased rate of cardiac events when on vs off ASMs (0.59 vs 1.82 events per 100 person years, respectively). LQTS1 and LQTS2 participants had similar baseline QTc durations and prevalence of cardiac events (Table  I and Supplementary Table II) . There were LQTS genotype-specific differences in the rate and risk of cardiac events when on vs off ASMs. LQTS2 participants had a 1.8-fold higher rate of cardiac events when on ASMs, whereas LQTS1 participants had a 65% reduction in the rate of cardiac events when on ASMs (Fig 2A) . In a multivariate model of LQTS1 and LQTS2 participants, which included a stratification term for sex and adjustments for baseline QTc duration, and time-dependent beta blocker and ASM usage, there was an increased risk of cardiac events when LQTS2 (HR 1.47, 95% CI 1.02-2.12, P = 0.039), but not LQTS1 participants (HR 0.47, 0.20-1.11, P = 0.084), were on ASMs (interaction, P = 0.016, Fig 2B) . Subanalyses of the rate/risk of ventricular tachyarrhythmias and aborted cardiac arrest/SCD yielded similar results to the composite end point of cardiac events (Supplementary Table III) .
Predominant mechanism of ASM action confers differing risks of cardiac events. We investigated the rate of cardiac events on vs off each class of ASMs. As shown in Supplementary Table I, the number of participants with a history of each type of ASM therapy, and the total time on each class of ASMs, were similar in LQTS1 and LQTS2 participants. Participants with QTc prolongation, including LQTS2, had a 2-fold higher rate of cardiac events when on vs off Na + channel blocker ASMs ( Fig  3, A and C) . In contrast, there was an 80% lower rate of cardiac events when LQTS1 participants were on vs off Na + channel blocker ASMs ( Fig 3B) . Due to multiple mechanisms of ASM action and polytherapy, in a single multivariate model, we assessed the risk of cardiac events when on each class of ASM; off all ASMs was the reference. Time-dependent Na + channel blocker ASM therapy were associated with LQTS genotype-specific differences in the risk of cardiac events. There was an increased risk of cardiac events when participants with QTc prolongation (P < 0.001), including LQTS2 participants (P = 0.011), were on Na + channel blocker ASMs (Fig 3, D and F) . In contrast, there was a decreased risk of cardiac events when LQTS1 participants were on Na + channel blocker ASMs (P < 0.050, Fig 3E) . Regardless of the group, time-dependent GABA modifier ASM use was not associated with a change in the risk of cardiac events (Fig 3, D-F ). In participants with QTc prolongation, concurrent Na + channel blocker, and GABA modifier, ASM usage was associated with a significantly increased risk of cardiac events ( Fig 3D) .
We confirmed these results by assessing the risk of cardiac events when on select ASMs, in which the predominant mechanism of action was either Na + channel blockade (e.g. phenytoin) or GABA modification (e.g. phenobarbital.) Consistent with Fig 3,  there were LQTS genotype differences in the risk of cardiac events when Adjustments for time-dependent beta-adrenergic blocker use, baseline QTc duration, and stratified for sex. We estimated the LQTS genotype-specific effects using an interaction term in the model. LQTS, Long QT syndrome; ASMs, antiseizure medications; ACA, aborted cardiac arrest; SCD, sudden cardiac death; QTc, corrected QT.
LQTS1 and LQTS2 participants were on phenytoin (P = 0.020, Supplementary Fig 1) . Furthermore, LQTS2 participants were at an increased risk of cardiac events when on phenytoin (P < 0.001). There was no difference in the risk for cardiac events when LQTS1 or LQTS2 participants were on phenobarbital.
Concurrent beta-adrenergic blocker ASM therapy and participant gender are associated with differences in the risk of cardiac events. As beta-adrenergic blockers are the major form of antiarrhythmic therapy for LQTS, 19 all above analyses included a covariate for time-dependent beta-adrenergic blocker therapy. In addition, in participants with QTc prolongation we examined the timedependent risk of recurrent cardiac events when participants were on ASMs in the absence and copresence of beta-adrenergic blockers. In the absence of concurrent beta-adrenergic blocker therapy, all ASMs and each class of ASMs were associated with an increased risk of cardiac events (Fig 4, A and C) . In contrast, concurrent beta-adrenergic blocker and ASM treatment blunted the increased risk for cardiac events (with vs without betaadrenergic blocker interaction; all ASMs, P < 0.001, Na + channel blocker ASMs, P < 0.001). There were no differences in the risk of cardiac events when on GABA modifier ASMs (P = 0.094) or concurrent Na + channel blocker and GABA modifier ASMs (P = 0.546) in the absence vs copresence of beta-adrenergic blockers (Fig 4C) . Similar ASM class-specific analyses in LQTS1 and LQTS2 participants with QTc prolongation were not possible due to an insufficient number of participants and events on or off beta-adrenergic blockers.
As the risk of cardiac events differ in male vs female participants, 20, 24, 25 all analyses included a nonparametric adjustment term for sex. Further analyses indicated that male and female participants with QTc prolongation differ in their risk of cardiac events when on all ASMs (male vs female interaction, P < 0.001), GABA modifier ASMs (P = 0.027), and concurrent Na + channel blocker and GABA modifier ASMs (P = 0.011, Fig 4,  B and D) . Female participants with QTc prolongation were at an increased risk of cardiac events when on all ASMs, Na + channel blocker ASMs, GABA modifier ASMs, and concurrent Na + channel blocker and GABA modifier ASMs (Fig 4, B and D) . Similarly, female LQTS2 participants with QTc prolongation were at an increased risk of cardiac events when taking all ASMs (female: HR 1.86, 95% CI 1.23-2.82, P = 0.003; male: HR 0.64, 95% CI 0.27-1.52, P = 0.308; male vs female interaction, P = 0.029). Similar to the overall LQTS1 population (Fig 2B) , LQTS1 male and female participants each exhibited a nonsignificant reduction in the risk of cardiac events when on all ASMs (male, HR 0.59, 95% CI 0.05-5.48, P = 0.645; female, 0.45, 0.17-1.15, P = 0.095; male vs female interaction, P = 0.820). There was not enough power to calculate the hazard ratios for male and female LQTS1 and LQTS2 participants on each class of ASMs.
High sensitivity analyses. We also confirmed the aforementioned results by performing high sensitivity analyses in symptomatic participants (≥1 cardiac event during follow-up). Consistent with Fig 2, participants with QTc prolongation, including LQTS2 participants, exhibited a 1.9-to 2.6-fold higher rate and increased risk of cardiac events when on vs off ASMs (P < 0.001, Supplementary  Fig 2) . On the other hand, LQTS1 patients exhibited a 52% reduced rate and a lower risk for cardiac events when on ASMs (P = 0.008). Furthermore, we confirmed that LQTS genotype, predominant mechanism of ASM action, concurrent beta-adrenergic blocker therapy, and female sex are all associated with differing risks of cardiac events when on vs off ASMs (Supplementary Figs 3 and 4) .
To enable more rigorous "high sensitivity" analyses, we limited our analyses to participants with a cardiac event before the initiation of the first ASM. This refinement reduced the number of participants in each group, which unfortunately limited our ability to perform multivariate risk analyses. Nevertheless, in this refined cohort, timedependent ASM therapy was associated with an increased rate of cardiac events among all participants with QTc prolongation, including LQTS2 participants, but a reduced rate in LQTS1 participants (Supplementary Table IV) .
ECG measures when LQTS participants were on and off
ASMs. In a subset of participants with ECG recordings during periods of on and off ASMs, we tested for differences in ECG measures when on vs off ASMs (Table II and Supplementary Table V) . In male participants with QTc prolongation, the QTc duration was shorter when on vs off GABA modifier ASMs. Also, participants with QTc prolongation had slower heart rates when on vs off all and Na + channel blocker ASMs. All other QTc, heart rate, and QRS measurements did not differ when each group of patients, including male and female participants with QTc prolongation, were on vs off all ASMs and each class of ASMs. Subanalyses indicated that patients with a longer QTc duration when on vs off ASMs were at a higher risk of cardiac events when on vs off ASMs (HR 4.03, 95% CI 2.69-6.06, P < 0.001), compared to those with QTc shortening when on vs off ASMs (HR 1.26, 95% CI 0.83-1.91, P = 0.274, interaction P < 0.001).
DISCUSSION
In LQTS patients and their affected family members with a history of ASM therapy, we assessed the time-dependent risk of recurrent cardiac events when participants were taking ASMs vs off all ASMs. This study reveals that when selecting ASMs in patients with prolonged QTc durations, one should carefully consider LQTS genotype, predominant mechanism of ASM action, concurrent beta-adrenergic blocker therapy, and female sex. Our results establish a platform for LQTS patientspecific predictions for the risk of cardiac events when taking ASMs, and thus, help to guide future LQTS patient/ genotype-specific ASM interventions.
Drugs are often repurposed to treat additional pathologies. For example, numerous antiarrhythmic drugs produce proconvulsant and anticonvulsant effects. 9 Ranolazine and GS967, which are late Na + channel blocker antiarrhythmic agents originally used to treat angina pectoris, 26 also reduce neuronal Na + current, spontaneous, and repetitive hippocampal and pyramidal neuron firing, the number of seizures, and improve survival in several models of epilepsy. 27, 28 Quinidine, a class IA antiarrhythmic drug, reduces the incidence of seizures and improves psychomotor development in migrating partial seizures of infancy, secondary to a gain-of-function mutation in KCNT1. 29 In contrast to the dual efficacy of many drugs, numerous drugs (e.g., some antihistamines, antipsychotics, antidepressants, and antimicrobials agents) exert substantial off-target cardiac effects including QTc prolongation and increased risk for developing lethal ventricular arrhythmias. 3, 18, 30 Despite numerous cellular studies, 13, 14 patient case studies, 9-11 and a recent review, 12 it remains unclear, with often competing results, whether ASMs are associated with changes in ECG measures, and the risk of arrhythmias and SUDEP. For example, cellular expression studies indicate that lamotrigine, phenytoin, and phenobarbital inhibit IKr, which is mutated in LQTS2 and critical for cardiomyocyte repolarization. 13, 14 Lamotrigine slows the rate of depolarization and contraction in isolated myocytes/tissue. 16 In contrast, clinical studies in healthy people and elderly patients with newly diagnosed epilepsy indicate that lamotrigine does not alter the QTc or QRS duration. [15] [16] [17] Phenytoin is associated with arrhythmias due to QTc prolongation and atrioventricular block. 9 Yet, other studies report phenytoin has no effect on the QTc duration or risk of arrhythmias, 10 or even that it suppresses arrhythmias.
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Therapeutic serum levels of carbamazepine promote bradycardia and induce atrioventricular delay/block. 31, 32 Several ASMs, carbamazepine, and lamotrigine in particular, suppress autonomic tone, and thus, predispose patients to arrhythmias. 33, 34 Yet, another study in patients with medical refractive epilepsy reported no change in any ECG measures or autonomic tone (i.e., heart rate variability) on withdraw of ASMs. 8 Importantly, although ASMs may be safe in the general population with normal QTc intervals, it remains unknown whether ASMs are associated with a change in the risk of arrhythmias in patients genotype/phenotype positive for LQTS. This is a major premise of the present study; as patients with LQTS are at risk of seizures, 20, 21 and many are on ASMs, it is important to assess the cardiac safety of ASMs in these individuals (i.e., risk of cardiac events).
The clinical and genetic biomarkers for the highest risk of SUDEP remain incompletely understood. Cardiac arrhythmias are one of several proposed mechanisms for SUDEP. 35 Poor seizure control, ASM polytherapy, drugdrug interactions, and long duration epilepsy are all risk factors associated with arrhythmias and SUDEP. 1, 9, 35 ASM usage is associated with a 2.6-fold increase in the risk of SCD in people with and without epilepsy.
2 Similar to our results, SCD risk is greatest in people on Na + channel blocker ASMs; non-Na + channel blocker ASMs do not increase the risk of SCD. 2 Female patients with epilepsy are at a higher risk of SUDEP when on vs off lamotrigine. 36 Yet, as discussed previously, it remains incompletely understood whether ASMs are associated with an increased risk of arrhythmias and SUDEP [9] [10] [11] [12] in patients genotype/phenotype positive for LQTS.
Our results indicate that the risk of recurrent cardiac events was higher when people with an underlying alteration in cardiac electrical function (i.e., baseline QTc prolongation) were taking ASMs, particularly Na + channel blocker ASMs. In line with our results, phenobarbital (GABA modifier ASM) is not associated with QTc prolongation but rather has been shown to lead to QT shortening and arrhythmia suppression. 37 Future studies are needed to identify the molecular and electrophysiological mechanisms why LQTS2, but not LQTS1, patients are at an increased risk of cardiac events when on ASMs, as well as the effect that concurrent beta-adrenergic blocker therapy and patient gender have on the QTc duration and risk of cardiac events. It is plausible that a mild ASM-mediated reduction in I Kr may not reduce the repolarization reserve enough to effect the QTc and risk of arrhythmias in patients with normal levels of IKr. In contrast, since LQTS2 patients already have a reduction in IKr, an additional ASMmediated reduction in IKr (e.g., phenytoin and lamotrigine 13, 14 ) may serve as a "double hit" to reduce the repolarization reserve sufficient to promote the initiation of an arrhythmia. In LQTS, late Na + channel blockers (e.g., ranolazine and phenytoin) restore the balance between depolarizing and repolarizing current, reduce the rate of triggered activity, and thus exert antiarrhythmic effects. 11, 26 Future studies will be needed to determine the interplay between these proposed proarrhythmic/antiarrhythmic mechanisms.
As ASMs perturb ion channel function, 3,13,14 we hypothesized ASM-mediated alterations in ECG measures provide a potential explanation for changes in the risk of cardiac events when patients are on vs off ASMs. ECG measures in a subset of patients with resting ECG recordings each on and off ASMs for the most part do not suggest ASMs alter cardiac electrical function. Yet, the subset of patients that developed QTc prolongation when on ASMs were at an increased risk of cardiac events when on ASMs. In contrast, patients with QTc shortening when on ASMs did not exhibit a change in the risk of cardiac events when on ASMs. The lack of change in ECG measures challenges our above hypotheses of IKr and late Na + current blockade. Although QT prolongation is associated with ventricular arrhythmias, it is not a perfect surrogate of cardiac events. 38, 39 Also, it is important to note that this is a retrospective study and it was not designed to assess the effect of ASMs on the ECG. ECG measures need to be thoroughly examined prospectively in a larger cohort of patients, with predesigned protocols including repeated measurements, dose-dependent sampling, and controlled for various covariates. Importantly, LQTS patients develop arrhythmias in the presence of proarrhythmic triggers. 40 For example, LQTS1 patients develop arrhythmias during exercise, especially swimming. Emotional stress and auditory stimuli are associated with arrhythmias in LQTS2. These triggers were likely not present during these resting ECG recordings. Thus, it is possible that in the presence of LQTS proarrhythmic triggers, ASMs may be associated with changes in the QTc duration, and thus risk of cardiac events. Future LQTS patient, animal, and cellular studies in the presence of proarrhythmic triggers are needed to determine the mechanisms that underlie the LQTS genotype-specific proarrhythmic and antiarrhythmic effects of ASMs. LQTS is a multisystem disease. [20] [21] [22] 41 We recently demonstrated a 3-fold higher prevalence of seizures in LQTS genotype positive vs negative patients; seizures are the strongest independent risk factor for cardiac arrhythmias in LQTS patients. 20 However, the underlying mechanisms for these dual neurocardiac pathologies remain unknown. In addition to LQTS genes being expressed in the brain and heart, [42] [43] [44] this study demonstrates Na + channel blocker ASMs alter cardiac electrical function in ways that either decrease (LQTS1) or increase (LQTS2) a patient's risk for potentially fatal arrhythmias. These results establish the basis for future prospective clinical studies and database analyses, as well as mechanistic cellular, organ, and whole animal experimental studies. Future studies in a data set with comprehensive cardiac and neurological records and in an animal model with LQTS 42 will enable assessments of the interaction and temporal correlation between seizure and cardiac events in LQTS. In contrast to our previous study, this study did not compare patients with a history of ASM use (seizure group) vs no history of ASMs (nonseizure group). Within a population of patients that all took ASMs, we compared the time-dependent risk of cardiac events when they were taking (on) vs not taking (off) ASMs. In contrast to the increased risk of cardiac events in LQTS1 patients with vs without a history of seizures, 20 the present study indicates that regardless of a history of seizures, LQTS1 patients are actually at a decreased risk of cardiac events when on vs off Na + channel blocker ASMs.
Many ASMs are also prescribed for mood stabilization, pain management, and other conditions. Thus, similar to ASMs increasing the risk of SCD in non-epileptic patients, 2 our results extend beyond epilepsy and suggest caution when prescribing ASMs to patients with QTc prolongation.
Female LQTS patients are at a higher risk of arrhythmias, and the incidence of LQTS and drug related arrhythmias is higher in women. 45 Sex-specific differences in cardiac ion channel expression are observed following puberty. For example, there are lower levels of KCNH2, minK, Kir2.3, Kv1.4, KChIP2, SUR2, and Kir6.2 K + channel transcript and protein expression, and corresponding ion currents, in cardiac myocytes from female vs male animals/patients. 46, 47 An ASMmediated further reduction in these K + currents would reduce the amount of repolarizing current, which may increase the QTc duration and increase the susceptibility for the initiation of arrhythmias. 47, 48 In addition, L-type Ca 2+ current density is higher in hearts from female vs male animals. 47 Hearts from female animals exhibit greater dispersion of Na + channel density and repolarization. 45 Females patients after puberty have longer QTc durations. 48, 49 Differences in ion channel expression, action potential and QTc duration, and incidence of triggered/arrhythmogenic beats are reversed on the addition of testosterone to cardiomyocytes from female animals, orchiectomy, and ovaectomy. [45] [46] [47] [48] Many QTc prolonging (i.e., IKr blocking) drugs are associated with a higher incidence of arrhythmias in female vs male patients. 48 Thus, sex-specific differences in the time-dependent risk of recurrent cardiac events and QTc duration when participants are taking ASMs may be related to female patients having reduced and dispersion of repolarization reserve, due to lower levels of K + channel expression and higher levels of Ca 2+ channel expression. These sex-specific differences provide substrates for arrhythmogenesis.
Our study has limitations. This study was nonrandomized and retrospective up until the date of enrollment, thus limiting the amount of information available. However, after enrollment detailed patient, genetic, and physician reports documenting all medical events and therapeutic interventions were collected prospectively. Due to the absence or limited information available regarding ASM dosage, adherence, and the reason to start or stop all ASMs or specific classes of ASM therapy, it was not possible to control for these factors in the study. The LQTS registry has limited documentation of seizure events. Thus, we were not able to control for seizure severity/type or the antiseizure/ convulsant efficacy of ASMs. Although we showed an association between beta-adrenergic blocker therapy and the risk of cardiac events on vs off ASMs, we did not have enough participants and events to assess the impact of other cardiac therapies (Supplementary Table I) . Importantly, 31% of the participants had implantable cardiac defibrillators (ICDs). Although ICDs do not affect the susceptibility for cardiac events, they served to enhance our ability to capture cardiac events. LQTS3 patients are classically prescribed Na + channel blocker antiarrhythmic agents; however, there were only 11 LQTS3 participants with a history of ASM therapy. We did not have enough statistical power to assess the recurrent risk of cardiac events when LQTS3 participants were taking ASMs. Although there was not a higher rate of cardiac events when LQTS negative participants with normal QTc durations were on vs off ASMs, we were unable to perform recurrent risk analyses. Nevertheless, consistent with previous studies, 8, 10, [15] [16] [17] our results indicate that ASMs do not increase the rate of cardiac events within the general LQTS genotype-and phenotypenegative population.
People with QTc prolongation are at an increased risk of cardiac events when on vs off ASMs. Pharmacogenomic analyses indicate there are LQTS genotype and ASM class specific differences in the risk of cardiac events when patients are taking ASMs. Na + channel blocker ASMs are associated with an increased risk of cardiac events in LQTS2 patients and are protective in LQTS1 patients. Despite GABA modifier ASMs not being associated with a change in the overall risk of cardiac events, subanalyses indicate caution needs to be applied when initiating GABA modifier ASM therapy in the absence of beta-adrenergic blocker therapy, or GABA modifiers in female participants with QTc prolongation. In patients with QTc prolongation, the increased risk of cardiac events is blunted when ASMs are taken concurrently with betaadrenergic blockers. 
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RESULTS
Supplementary Table I lists detailed baseline characteristics. The number of participants and time taking each class of ASMs were similar in LQTS1 and LQTS2 participants. Moreover, a similar percentage of LQTS1 and LQTS2 participants exhibited a history of left cardiac sympathetic denervation, pacemakers, ICDs, and each beta-adrenergic blocking agent. Finally, there were no differences in the percentage of LQTS1 and LQT2 participants with a history of each type of cardiac event.
Supplementary Table II lists the specific ASMs taken by participants in this study and their predominant mechanism of action. The number of people in the overall study (QTc prolongation) and in the LQTS1 and LQTS2 groups that had a history of each ASM is listed. Several participants took more than 1 ASM during follow-up.
In the QTc prolongation group (n = 296), during a mean follow-up of 32 ± 11 years, 192 of 607 cardiac events were appropriate ICD shocks. In LQTS1 participants (n = 48), during a mean follow-up of 34 ± 10 years, 41 of 61 cardiac events were appropriate ICD shocks. In the LQTS2 group (n = 76), during a mean follow-up of 36 ± 8 years, 94 of 164 cardiac events were appropriate ICD shocks.
Supplementary Table III indicates that participants with QTc prolongation were at a higher risk of ventricular tachyarrhythmias and ACA/SCD when on ASMs. In LQTS1 participants, there was a nonsignificant decreased risk of ventricular tachyarrhythmias when on ASMs. The risk of ACA/SCD was higher when LQTS2 participants were on ASMs. Fig 3 of the main manuscript demonstrated that Na + channel blocker ASMs, but not GABA modifier ASMs, were associated with LQTS genotype-specific effects on the risk of cardiac events. Consistent with these results, phenytoin, a Na + channel blocker ASM, was associated with an increased risk of cardiac events in LQTS2 participants (LQTS1 vs LQTS2 interaction, P = 0.020, Supplementary Fig 1) . There was no difference in the risk of recurrent cardiac events when participants in each Supplementary Fig 4. High sensitivity analyses: concurrent beta-adrenergic blocker ASM therapy and participant gender affect the risk of recurrent cardiac events in participants with a history of cardiac events. Multivariate adjusted time-dependent analyses of the risk of cardiac events (ACA, SCD, and ventricular tachyarrhythmia) in participants with QTc prolongation when on all ASMs in the absence and copresence of beta blocker therapy (A) and in male vs female participants (B). Risk analyses of time-dependent Na + Ch blocker ASM, GABA modifier ASM, and concurrent Na + Ch blocker and GABA modifier ASM therapy in the absence and copresence of beta blockers (C) and in male vs female participants (D). Adjustments for time-dependent beta-adrenergic blocker use, baseline QTc duration, and stratified for sex. Panels C and D are also adjusted for time-dependent other ASM use. Differences in the risk of cardiac events on ASMs in the absence vs copresence of beta-adrenergic blocker therapy, and in male vs female participants were modeled using interaction terms.
of the groups were on phenobarbital, a GABA modifier ASM.
High sensitivity analysesFor high sensitivity analyses, the inclusion criteria was a history of ASMs, baseline QTc prolongation, and ≥1 ventricular arrhythmia (n = 156). The group was stratified by LQTS genotype to include LQTS1 (n = 19) and LQTS2 participants (n = 42). Similar to Fig 2, high sensitivity analysis indicated that participants with QTc prolongation, including LQTS2 participants, had a 1.9-to 2.6-fold higher rate of cardiac events when on vs off ASMs ( Supplementary Fig 2A) . Furthermore, the risk of cardiac events was higher in these patients while on ASMs (Supplementary Fig 2B) . In contrast, LQTS1 participants had a 52% reduction in the rate of cardiac events and a significantly reduced risk of cardiac events on ASMs (LQTS1 vs LQTS2 interaction, P < 0.001).
Next in 1 multivariate Anderson-Gill model, we assessed the recurrent risk of cardiac events on Na + channel blocker, GABA modifier, or concurrent Na + channel blocker and GABA modifier ASMs (reference, off all ASMs.) Participants with QTc prolongation, including LQTS2, had an increased risk of cardiac events on Na + channel blocker ASMs (Supplementary Fig 3) . Na + channel blocker ASMs were associated with a decreased risk of cardiac events in LQTS1 participants (P = 0.007.) In contrast to Fig 3 of the main manuscript, participants with QTc prolongation, including LQTS2, had an increased risk of cardiac events when on GABA modifier ASMs. Concurrent Na + channel blocker and GABA modifier ASM usage was associated with an increased risk of cardiac events in participants with QTc prolongation, including LQTS2.
Consistent with the results in main manuscript Fig 4 , high sensitivity analyses further confirmed that in the absence of beta blocker therapy, there was an increased risk of cardiac events when on all ASMs, Na + channel blocker ASMs, and concurrent Na + channel blocker and GABA modifier ASMs (Supplementary Fig 4, A and C) . The risk of cardiac events on ASMs was attenuated with concurrent beta-adrenergic blocker therapy (absence vs concurrent beta-adrenergic blocker therapy, all ASMs: P < 0.001; Na + channel blocker ASMs: P < 0.001). Female participants were at an increased risk of cardiac events when on all ASMs, Na + channel blocker ASMs, GABA modifier ASMs, and concurrent Na + channel blocker and GABA modifier ASMs (Supplementary Fig  4, B and D, male vs female interaction, all ASMs: P = 0.012; Na + channel blocker ASMs: P = 0.033; concurrent Na + channel blocker and GABA modifier ASMs: P = 0.043). In summary, high sensitivity analyses indicate LQTS genotype and predominant mechanism of ASM action are associated with differing risks for cardiac events.
To enable more rigorous "high sensitivity" analyses, we limited our analyses to participants with a cardiac event before the initiation of the first ASM. This refinement reduced the number of participants in each group, which unfortunately limited our ability to perform multivariate risk analyses. Nevertheless, in this refined cohort, timedependent ASM therapy was associated with an increased rate of cardiac events among all participants with QTc prolongation, including LQTS2 participants, but a reduced rate in LQTS1 participants (Supplementary Table IV) . In summary, LQTS genotype, beta-adrenergic blocker therapy, and female sex are associated with differing risks of cardiac events.
ASMs are not associated with changes in ECG measuresWe tested for differences in ECG measures on vs off ASMs. Measurements were obtained from baseline/ enrollment ECGs, and frequent follow-up ECG recordings/reports. Each patient had at least 1 ECG measurement both on and off ASMs. Although several previous studies suggested ASMs are associated with changes in the QTc duration, 1 in all groups, except male participants on GABA modifier ASMs, there were no differences in the average QTc duration (Table II) and QRS duration when on vs off all ASMs, Na + channel blocker ASMs, GABA modifier ASMs, or concurrent Na + channel blocker and GABA modifier ASMs (Supplementary Table  V) . Participants with QTc prolongation had slower heart rates on all ASMs and Na + channel blocker ASMs.
